Ratnakar Securities Pvt. Ltd.

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal

BSE2638.7512.5 (+0.48 %)

PREV CLOSE ( ) 2626.25

OPEN PRICE ( ) 2652.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 2383

TODAY'S LOW / HIGH ( )2609.15 2659.85

52 WK LOW / HIGH ( )2022.05 3115

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-12 1979

Management Info

Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director

Registered Office

Address Ajanta Tower, 54 - A,M V Road, Chakala,Andheri (East),
Mumbai,
Maharashtra-400093

Phone 022-60609000 / 66061000

Email legal.info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

06Nov Ajanta Pharma informs about transcrip
Further to its communication dated 3rd November 2025 on earnings call, p..

24Oct Ajanta Pharma informs about update on
With reference to its letter dated 8th October 2025, informing about the..

03Oct Ajanta Pharma informs about updates
Ajanta Pharma has informed that it enclosed Disclosure under Regulation..

16Sep Ajanta Pharma inform about disclosure
Ajanta Pharma has informed that it enclosed disclosure under Regulation..

02Sep Ajanta Pharma informs about analyst m
Pursuant to Regulation 30 of the Securities and Exchange Board of India..

Financials

in Millions

	QTR Sep 25	ANNUAL 25
Net Profit	2495.3	9168.9
Gross Profit	3219.7	11800.6
Operating Profit	3646.2	13245.9
Net Sales	12202.4	43220.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Alkem Laboratories (BSE) 5689.30 (1.38%)	M.Cap ( in Cr)68024.12
Abbott India (BSE) 28869.35 (0.15%)	M.Cap ( in Cr)61345.35
Glaxosmithkline Phar (BSE) 2543.10 (1.35%)	M.Cap ( in Cr)43081.65
Wockhardt (BSE) 1360.10 (2.16%)	M.Cap ( in Cr)22100.56
RPG Life Sciences (BSE) 2228.80 (1.27%)	M.Cap ( in Cr)3686.22

Shareholding Pattern

	NON-INSTITUTION	7.32%
	PROMOTERS	66.25%
	FI/BANKS/INSURANCE	2.64%
	MUTUAL FUNDS/UTI	14.67%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
UTI Healthcare Fund...	5.48
Aditya Birla SL Pha...	3.75
PGIM India Healthca...	3.27
NJ ELSS Tax Saver S...	3.20
Tata India Pharma &...	2.97
Baroda BNP Paribas ...	2.91

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

AJANTA PHARMA LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES